The Board proposes the rule amendment to remove the reference to Rule Chapter 59A-7, F.A.C., from the rule text.

 

DEPARTMENT OF HEALTH

Board of Clinical Laboratory Personnel

RULE NOS.:RULE TITLES:

64B3-13.002Responsibilities of Supervisors

64B3-13.003Responsibilities of Technologists

PURPOSE AND EFFECT: The Board proposes the rule amendment to remove the reference to Rule Chapter 59A-7, F.A.C., from the rule text.

SUMMARY: To update rule text.

SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS AND LEGISLATIVE RATIFICATION:

The Agency has determined that this will not have an adverse impact on small business or likely increase directly or indirectly regulatory costs in excess of $200,000 in the aggregate within one year after the implementation of the rule. A SERC has not been prepared by the Agency.

The Agency has determined that the proposed rule is not expected to require legislative ratification based on the statement of estimated regulatory costs or if no SERC is required, the information expressly relied upon and described herein: During discussion of the economic impact of this rule at its Board meeting, the Board concluded that this rule change will not have any impact on licensees and their businesses or the businesses that employ them. The rule will not increase any fees, business costs, personnel costs, will not decrease profit opportunities, and will not require any specialized knowledge to comply. This change will not increase any direct or indirect regulatory costs. Hence, the Board determined that a Statement of Estimated Regulatory Costs (SERC) was not necessary and that the rule will not require ratification by the Legislature. No person or interested party submitted additional information regarding the economic impact at that time.

Any person who wishes to provide information regarding a statement of estimated regulatory costs, or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.

RULEMAKING AUTHORITY: 483.805(4) , 483.823 FS.

LAW IMPLEMENTED: 483.800, 483.813, 483.823, 483.825 FS.

IF REQUESTED WITHIN 21 DAYS OF THE DATE OF THIS NOTICE, A HEARING WILL BE SCHEDULED AND ANNOUNCED IN THE FAR.

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Anthony B. Spivey, Executive Director, Board of Clinical Laboratory Personnel, 4052 Bald Cypress Way, Bin # C07, Tallahassee, Florida 32399-3257.

 

THE FULL TEXT OF THE PROPOSED RULE IS:

 

64B3-13.002 Responsibilities of Supervisors.

(1) No change.  

(2) In addition, the supervisor shall fulfill the following responsibilities:

(a)  through (z) No change. 

(aa) In the specialty of Cytology, in addition to the above responsibilities, the supervisor shall, if responsible for screening cytology slide preparations, document the number of cytology slides screened in 24 hours and the number of hours devoted during each 24 hour period to screening of cytology slides, as indicated in Rule Chapter 59A-7, F.A.C. The supervisor shall be responsible for and be required to provide this information to any laboratory for which the individual screens slides.

Rulemaking Authority 483.805(4) FS. Law Implemented 483.800, 483.813, 483.823, 483.825 FS. History–New 12-6-94, Amended 3-28-95, Formerly 59O-13.002, Amended 4-10-01, 4-7-02,               .

 

64B3-13.003 Responsibilities of Technologists.

(1) No change.

(2) In addition the technologist shall fulfill the following responsibilities.

(a) through (g) No change. 

(h) Exercises professional judgment in evaluation, specimen integrity, result accuracy and inter-result validity and takes corrective action as necessary. Such corrective action shall include specimen rejection, recollection, and/or retesting using the same or alternate methods and/or utilizes other skills associated with the practice of clinical laboratory science to ensure validity and accuracy of testing at all times taking care not to compromise patient care with excessive rejections, recollections or delays. If in their judgment a specimen is compromised, the technologist shall include an appropriate disclaimer statement in the report indicating the potential compromised nature of the result and why, in accordance with Rule Chapter 59A-7, F.A.C.

(i) No change.

(j) In the specialty of Cytology, in addition to the above responsibilities, the technologist shall:

1. Document slide interpretation results of each gynecologic and nongynecologic cytology case he or she examined or reviewed as specified in Rule Chapter 59A-7, F.A.C., and the clinical laboratory’s policies and procedure.

2. through 3. No change.

Rulemaking Authority 483.805(4), 483.823 FS. Law Implemented 483.800, 483.813, 483.823, 483.825 FS. History–New 12-6-94, Amended 3-28-95, 7-12-95, 12-4-95, Formerly 59O-13.003, Amended 4-10-01, 4-7-02,                 .

 

NAME OF PERSON ORIGINATING PROPOSED RULE: Board of Clinical Laboratory Personnel

NAME OF AGENCY HEAD WHO APPROVED THE PROPOSED RULE: Board of Clinical Laboratory Personnel

DATE PROPOSED RULE APPROVED BY AGENCY HEAD: May 29, 2019

DATE NOTICE OF PROPOSED RULE DEVELOPMENT PUBLISHED IN FAR: July 8, 2019